Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QuANTUM-Wild: quizartinib or placebo with induction/consolidation chemotherapy and maintenance in newly diagnosed FLT3-ITD negative AML
2023-507936-20-00Phase 3Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Quizartinib arm with Placebo arm (2 arms). Primary endpoint: Overall survival. Planned start May 2025; status: authorised.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-507936-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507936-20-00.